| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/02/2006 | WO2006000324A3 New mao-b inhibitors |
| 03/02/2006 | WO2005123679A3 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/02/2006 | WO2005113542A3 N-cyclic sulfonamido inhibitors of gamma secretase |
| 03/02/2006 | WO2005084714A3 Raav-neprilysin compositions and methods of use |
| 03/02/2006 | WO2005046667A3 System a transport inhibitors for treating or preventing neuropsychiatric disorders |
| 03/02/2006 | WO2005012513A8 Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regenaration |
| 03/02/2006 | WO2003077875A3 Proteins associated with growth, differentiation, and death |
| 03/02/2006 | WO2003070902A3 Receptors and membrane-associated proteins |
| 03/02/2006 | US20060047119 Analgesics with use of treating pain and as immunomodulators and for treatment of drug dependence |
| 03/02/2006 | US20060046992 Heterobicyclic compounds |
| 03/02/2006 | US20060046979 Organic compounds |
| 03/02/2006 | US20060045853 Using tissue plasminogen activator finger domain specific immunolglobulins as tool in diagnosis of diabbetes and/or alzheimer's disease |
| 03/02/2006 | DE60108394T2 Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten Sulfonyl-pyrrolidine derivatives suitable for the treatment of neurological diseases |
| 03/02/2006 | DE102004039196A1 Neue Formulierung für L-Tryptophan New formulation of L-tryptophan |
| 03/02/2006 | DE102004032567A1 Substituierte 1-Propiolyl-piperazine Substituted 1-piperazine-propiolyl |
| 03/02/2006 | CA2578407A1 Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| 03/02/2006 | CA2577926A1 Nutritional composition comprising immunoglobulins and oligosaccharides |
| 03/02/2006 | CA2577857A1 Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
| 03/02/2006 | CA2577782A1 Pyrrolo-naphthyl acids as pai-1 inhibitors |
| 03/02/2006 | CA2577677A1 Modulators of muscarinic receptors |
| 03/02/2006 | CA2577676A1 Process for production of microbial fat/oil containing discretional amount of diacylglycerol and said fat/oil |
| 03/02/2006 | CA2577511A1 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase ie |
| 03/02/2006 | CA2577089A1 Sigma receptor inhibitors |
| 03/02/2006 | CA2577061A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 03/02/2006 | CA2575461A1 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction |
| 03/02/2006 | CA2574454A1 Aminopiperidine derivatives, preparation thereof and use thereof as melanocortin receptor agonists |
| 03/02/2006 | CA2573125A1 Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
| 03/01/2006 | EP1630230A2 Streptococcus pneumoniae proteins and nucleic acids |
| 03/01/2006 | EP1630165A1 [1,2,4 ]triazolo [1,5-a]pyrimidin-2-ylurea derivative and use thereof |
| 03/01/2006 | EP1630162A1 2-aminoquinoline derivative |
| 03/01/2006 | EP1630159A1 5-HT7 receptor antagonists |
| 03/01/2006 | EP1630158A1 5-HT7 receptor antagonists |
| 03/01/2006 | EP1630156A1 Sertraline hydrochloride polymorphs |
| 03/01/2006 | EP1629845A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 03/01/2006 | EP1629843A2 Reboxetine for treating chronic fatigue syndrome |
| 03/01/2006 | EP1629841A1 Antidepressants or food and drinks for antidepression |
| 03/01/2006 | EP1629839A1 Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain |
| 03/01/2006 | EP1629837A1 Antistress agent |
| 03/01/2006 | EP1628994A2 Method for identifying modulators of g protein coupled receptor signaling |
| 03/01/2006 | EP1628980A1 6-arylmethyl-substituted pyrazolopyrimidines |
| 03/01/2006 | EP1628978A2 Triaza-spiro compounds as nociceptin analogues and uses thereof |
| 03/01/2006 | EP1628975A2 Jnk inhibitors |
| 03/01/2006 | EP1628968A1 4-imidazolin-2-one compounds |
| 03/01/2006 | EP1628963A1 Novel ureido - and amido-pyrazolone derivatives |
| 03/01/2006 | EP1628960A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 03/01/2006 | EP1628676A1 Grf analog compositions and their use |
| 03/01/2006 | EP1628662A1 Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor |
| 03/01/2006 | EP1628661A2 Modulators of vr1 receptor |
| 03/01/2006 | EP1628660A2 Methods and compositions for modulating serum cortisol levels |
| 03/01/2006 | EP1628656A2 Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use |
| 03/01/2006 | EP1628652A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
| 03/01/2006 | EP1628649A2 Neuroprotective benzoate and benzamide compounds |
| 03/01/2006 | EP1628648A1 Deramciclane-fumarate tablets |
| 03/01/2006 | EP1528922B1 Use of treosulfan and derivatives thereof for treating multiple sclerosis |
| 03/01/2006 | EP1494691A4 Treatment of diseases involving defective gap junctional communication |
| 03/01/2006 | EP1472255B1 Aza-arylpiperazines |
| 03/01/2006 | EP1414426B1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 03/01/2006 | EP1363910B1 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| 03/01/2006 | EP1347971B1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 03/01/2006 | EP1345942B1 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists |
| 03/01/2006 | EP1339710B1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 03/01/2006 | EP1324774B1 Use of a ppar delta activator for treating inflammatory conditions |
| 03/01/2006 | EP1319007B1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/01/2006 | EP1311507B1 Fused pyrazole derivatives being protein kinase inhibitors |
| 03/01/2006 | EP1307192B1 Candesartan for treating migraine |
| 03/01/2006 | EP1233962B1 Novel heterocyclic compounds and their use as medicines |
| 03/01/2006 | EP1173764B1 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12 |
| 03/01/2006 | EP1105409B1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 03/01/2006 | EP1062517B1 Diagnosis of spongiform encephalopathies using prionins |
| 03/01/2006 | EP0969845B1 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
| 03/01/2006 | EP0750507B2 Proteasome regulation of nf-kappa-b activity |
| 03/01/2006 | CN1742013A Pyrazolopyrimidine compound and method for producing the same |
| 03/01/2006 | CN1742011A 8-aza-bicyclo (3.2.1) octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/01/2006 | CN1742006A Benzofurane derivatives and the use of the same as antidepressants and anxiolytics |
| 03/01/2006 | CN1742001A Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands |
| 03/01/2006 | CN1741999A Pyridazinone derivatives as GSK-3beta inhibitors |
| 03/01/2006 | CN1741995A Isoindoline derivative |
| 03/01/2006 | CN1741990A Arylalkylcarbamate derivatives production and use thereof in therapy |
| 03/01/2006 | CN1741820A Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 03/01/2006 | CN1741819A Sustained release composition for oral administration of drugs |
| 03/01/2006 | CN1741803A Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 03/01/2006 | CN1741791A A composition material for transmucosal delivery |
| 03/01/2006 | CN1740193A Non-amidated omega-conotoxin VIIA and its prepn process and application |
| 03/01/2006 | CN1740167A Citalopram salt preparing and purifying process |
| 03/01/2006 | CN1740151A 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 03/01/2006 | CN1740150A 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 03/01/2006 | CN1739800A Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 03/01/2006 | CN1739787A Orally administered peptides to ameliorate atherosclerosis |
| 03/01/2006 | CN1739785A Chinese herbal medicine decoction for treating primary wet-type sciatica and its prepn |
| 03/01/2006 | CN1739784A Chinese medicine decoction for treating senile dementia caused kidney and spleen deficiency and its prepn |
| 03/01/2006 | CN1739776A Chinese herbal medicine decoction for treating senile dementia caused by marrow sea deficiency |
| 03/01/2006 | CN1739770A Chinese medicine composition for treating depression and neurosis |
| 03/01/2006 | CN1739744A Production process of flavone compound powder |
| 03/01/2006 | CN1739743A Medicine for treating parkinson's disease and Parkinson's syndrome and its prepn |
| 03/01/2006 | CN1739727A Chinese medicine process for treating anxiety neurosis and its prepn |
| 03/01/2006 | CN1739716A Chinese medicine decoction for treating senile dementia caused by liver and kidney deficiency and its prepn |
| 03/01/2006 | CN1739671A Tranquilizing and blood nourishing oral liquid |
| 03/01/2006 | CN1739655A Quality control method of Qingkailing injection prepn |
| 03/01/2006 | CN1739652A Chinese medicine prepn with functions of clearing away heat and toxic matter and tranquilizing and its prepn process |
| 03/01/2006 | CN1739648A Antidepressant Chinese medicine prepn and its prepn process and quality control method |